XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreements, License Agreement and Revenues - Product Revenue, Net - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue $ 55,902 $ 36,161  
Contract with Customer, Liability [Abstract]      
Deferred revenue, net of current 147,118   $ 157,555
Net unbilled milestone and co-development revenue 0   0
Constrained for Future Recognition [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue 2,600 2,100  
Product Revenue, Net [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Total revenue 30,538 $ 24,161  
China [Member] | Product Revenue, Net [Member]      
Contract with Customer, Liability [Abstract]      
Contract with customer liability increase decrease in revenue due to changes to estimated variable consideration 2,100    
AstraZeneca Agreements [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 176,631   179,851
Deferred revenue, net of current 149,700    
Net unbilled milestone and co-development revenue 22,900   22,500
AstraZeneca Agreements [Member] | China performance obligation [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 176,600    
Net unbilled milestone and co-development revenue 26,900    
AstraZeneca Agreements [Member] | China [Member]      
Contract with Customer, Liability [Abstract]      
Deferred Revenue 5,000    
Beijing Falikang Pharmaceutical Co Ltd | Product Revenue, Net [Member]      
Contract with Customer, Liability [Abstract]      
Reductions to gross accounts receivable $ 3,400   $ 3,000